Skip to main content

Status: retatrutide is not approved for sale or use anywhere in the world, including the UK. Anything sold as retatrutide is unlicensed and illegal to supply.

yezz.
Safety warning · Read this first

There is no real retatrutide for sale. Not in the UK. Not anywhere.

Retatrutide is an investigational medicine. It has not been approved for sale or use in any country in the world — so anything being sold as “retatrutide” right now is something else entirely, and injecting it is a gamble with no safety net.

Independently written · Last reviewed: · editorial policy

Key facts in 30 seconds

  • Retatrutide has no marketing authorisation in the UK, the US, the EU or anywhere else — there is no legal supply chain on Earth.
  • Anything sold as “retatrutide” — vials, pens, “research peptides” — is an unlicensed product, illegal to supply for human use in the UK.
  • The one-line test: a genuine product cannot be for sale before authorisation. That single fact settles every listing.
  • Independent testing of grey-market GLP-1 products has repeatedly found wrong doses, contamination and entirely different substances.
  • Already bought or used it? Do not inject, report the seller via the MHRA Yellow Card scheme, and use NHS 111 or 999 if you feel unwell.

The facts of the legal position

  • The UK: retatrutide has no entry in the MHRA products register. It is not a licensed UK medicine, so no UK pharmacy can legally dispense it and no UK prescriber can legally prescribe it — privately or on the NHS.
  • The US: the FDA has approved nothing. Eli Lilly itself says it plans to submit a Biologics License Application in the first quarter of 2027. A planned filing is not approval; a decision would realistically come no earlier than late 2027 to 2028.
  • Everywhere else: no regulator — the EMA, Health Canada, Australia's TGA, Japan's PMDA or any other — has authorised retatrutide. There is no legal supply chain for it on Earth.

The only legitimate access is through a registered clinical trial, or Lilly's small expanded-access programme in the US, which has strict eligibility criteria and does not operate in the UK.

Why this market exists at all

The demand is real: TRIUMPH-1's 28.3% average weight loss made global headlines in May 2026, and every news cycle since has added buyers. Where headlines create demand and regulation lags years behind, illegal sellers fill the gap. The MHRA and partner agencies have spent 2026 dismantling parts of the unlicensed GLP-1 supply chain, but new storefronts appear faster than old ones close.

Red flags: how to spot a fake retatrutide seller

  • It exists at all. A genuine product cannot be for sale before authorisation. This single fact settles every listing.
  • “Research use only” labels alongside photos of injection pens, dosing guides or before-and-after pictures.
  • No GPhC-registered pharmacy behind the sale, no prescription required, no clinical consultation.
  • Quoted prices. Lilly has announced no brand name and no price. Any number on a sales page is invented.
  • Crypto, bank-transfer-only or WhatsApp ordering, no UK company details, no verifiable address.
  • Shipping “from UK stock”. There is no legitimate UK stock to ship.

If you have already bought or used it

  • Do not inject any vial or pen bought outside a pharmacy. Keep the product and packaging unopened if you can.
  • Report the seller to the MHRA's Yellow Card scheme and, for illegal supply, to the MHRA directly.
  • If you have already injected and feel unwell — severe nausea, abdominal pain, signs of allergy, or anything that frightens you — contact NHS 111, your GP, or 999 in an emergency. Take the product with you; knowing what was actually in it matters.

What about joining a real trial?

Legitimate retatrutide studies run through the TRIUMPH programme and NHS clinical research. Most UK recruitment targets specific groups (for example, people with obesity plus a related condition), places are limited, and you should only ever enrol through an official trial page or your care team — never via an advert that promises access for a fee. Real trials never charge participants for the medicine.

The one-line version

Nobody can sell you retatrutide legally, because nobody — not even Eli Lilly — is allowed to sell it yet. If a site says otherwise, that sentence tells you everything about the site.

For the authorised alternatives available in the UK today, see our comparison page and when retatrutide could realistically reach the UK.

Cite this page

Johnson N. Yezz — independent UK retatrutide information. Medstack Ltd, 10 September 2026. https://yezz.co.uk/no-real-retatrutide-for-sale

Sources

Every factual claim on this page traces to one of these primary sources. We link out so you can check the original.

  1. 1.MHRA products register — the official list of licensed UK medicines — retatrutide is absent
  2. 2.Retatrutide UK: availability, trial results and legal status — UK availability and MHRA position, updated 31 July 2026
  3. 3.Retatrutide approval status and evidence 2026 — includes a direct MHRA register check, verified 30 August 2026
  4. 4.Eli Lilly development and FDA status — BLA filing plan for Q1 2027, announced 23 July 2026
  5. 5.Report a suspect medicine — MHRA Yellow Card — report fake, falsified or unlicensed products